Skip to content

    Recently Viewed

      Listening...

      Hand holding vial in front of DNA graphic

      How your own DNA could someday save your vision

      Imagine living with a genetic disease that could cause blindness in your 40s—and your doctor tells you there are no treatment options. It’s for patients like these that Johnson & Johnson is harnessing cutting-edge technology in the hope of finding real solutions.

      Share Article
      share to

      It can be devastating to watch someone slowly lose their vision.

      Dr. James List, M.D., Ph.D.

      Dr. James List

      Just ask James List, M.D., Ph.D., Global Therapeutic Area Head of Cardiovascular, Metabolism and Retina at Janssen Research & Development, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Before he joined the company in 2014, the Harvard endocrinologist spent his days counseling patients with diabetes. “Many people don’t realize that diabetes can cause irreversible damage to multiple organs, including the eyes,” he says.

      The urgent need for treatments to restore or preserve vision has remained top of mind since Dr. List took on his role at Johnson & Johnson to lead a global pharmaceutical team focused on creating innovative solutions to improve the lives of those living with cardiovascular, metabolic and retinal diseases.

      “We’re able to harness science and the power of the company to potentially offer hope to those living with devastating eye diseases that threaten to rob their vision,” he says. “There’s a lot of promising science—and a huge amount of unmet need.”

      Indeed, the company has been hard at work, including making progress on investigational gene therapies, one of which could potentially improve vision among people with a rare genetic eye disease.

      Retinitis pigmentosa (RP) is an uncommon genetic disorder that involves a breakdown and loss of cells in the retina, the light-sensitive tissue that lines the back of the eye. Up to 20% of the time, this is due to a mutated gene, RPGR, that’s passed down from the mother, resulting in a form of RP known as X-Linked RP (XLRP)—an X-chromosome-linked disorder that affects one in 40,000 people worldwide.

      The disease, which mostly affects males, is usually diagnosed in adolescence or young adulthood and begins with night blindness and a loss of peripheral vision.

      “Patients develop tunnel vision, where they can see directly in front of them but lose the ability to see on the side,” says Dr. List. “Over the years, that tunnel gets smaller and smaller until they become legally blind, usually in their 40s. It’s a disease with serious consequences.”

      Unfortunately, there are currently no treatments available for any form of RP, which is why the Janssen Pharmaceutical Companies of Johnson & Johnson are passionate about working to uncover therapies for this disease. “Anything that we can do to slow or halt the progression of XLRP has the potential to be life-changing,” says Dr. List.

      For National DNA Day, Dr. List explains this revolutionary work—what it is, how it’s done and what promise it holds.

      A therapy with potential promise for retinal disease

      Representation of the vision of a person with retinitis pigmentosa

      What vision loss caused by retinitis pigmentosa can look like

      Gene therapy is one of the ways Janssen aims to significantly improve health outcomes for patients.

      During gene replacement therapy, a person is injected with a healthy gene to replace a damaged or mutated one. While the concept has been around since the late 1970s, the science is so complex that it wasn’t tried on humans until 1990. Since then, it’s been studied to treat a variety of diseases, including certain cancers, cystic fibrosis and hemophilia.

      There’s a particular appeal to studying the use of gene therapy to treat inherited retinal disorders because “in these diseases, the cause is due to a single gene not working properly,” explains Dr. List.

      In the case of XLRP, the gene fails to produce a protein necessary for the proper functioning of photoreceptors, the cells in the retina that convert light into electrical signals that are then sent to the brain. “The goal of the investigational gene therapy is to take a working copy of the RPGR gene and inject its DNA into the photoreceptor cells to replace the nonfunctional gene,” Dr. List says. “Once the underlying defect is fixed, hopefully the disease can be addressed, or at least any more damage can be stopped.”

      The eye itself is an ideal target for gene therapy. “It’s physically accessible, and it also has ‘immune privilege,’ which means it’s able to tolerate the introduction of a foreign substance without immediately going into high alert and attacking it, unlike most other organs,” Dr. List explains. “Since it’s also very small, the amount of gene therapy required to treat it is relatively low, too.”

      Potential and promise in clinical trials

      In January 2019, Janssen entered into its first global collaboration with gene therapy company MeiraGTx to develop and commercialize gene therapies for the treatment of inherited retinal diseases, as well as to develop manufacturing technology.

      Two things made MeiraGTx such an appealing partner: They are leaders in the field of gene therapy, and they already had very strong relationships with hospitals and medical centers that specialize in inherited retinal diseases.

      “Our partnership is designed to ensure that we take advantage of the benefits both companies bring to the table, including MeiraGTx’s expertise in rare inherited retinal diseases and gene therapy combined with Janssen’s expertise in developing drugs and bringing them to the market,” says Penny Fleck, MT, MBA, Vice President, CVM Portfolio and Retinal Development, Janssen Research & Development, LLC.

      Ideally, we’d like to see patients get a therapy like this as early as possible in the course of their disease—potentially as soon as they’re diagnosed. The hope is that the earlier they start treatment, the more of their vision we can improve and preserve.
      James List, M.D., PhD.,

      This initial partnership and learnings, Fleck notes, “have enabled us to gain experience in this field, and we are extremely excited about how gene therapy can potentially be utilized to deliver life-changing therapies to patients who are either progressing to blindness or who are born with significant visual impairment where today there are no available treatments.”

      To do just that, the Janssen and MeiraGTx collaboration began clinical trials to test an experimental gene therapy at specialized eye centers in the United States and the United Kingdom. Potential candidates were required to undergo genetic testing to confirm their diagnosis.

      Looking toward the future of disease treatment

      A Janssen scientist at work on investigational gene therapy

      A Janssen scientist at work on investigational gene therapy

      The next step in the partnership’s journey is to test the investigational gene therapy in a larger phase 3 clinical trial. It’s already received Fast Track and Orphan designations from the U.S. Food and Drug Administration, which can help accelerate drug development for certain serious or rare diseases.

      “Ideally, we’d like to see patients treated with therapy like this as early as possible in the course of their disease—potentially as soon as they’re diagnosed,” says Dr. List. “The hope is that the earlier they start treatment, the more of their vision we can potentially help improve and preserve.”

      But this is just the first rung in what Dr. List hopes will be a long ladder of pharmaceutical gene therapy treatments.

      The company is also collaborating with MeiraGTx to investigate a gene therapy for the genetic retinal disorder achromatopsia, a condition in which patients cannot see colors.

      In December 2020, Janssen acquired the rights to Hemera Biosciences, LLC’s investigational gene therapy treatment: a one-time outpatient eye injection to help preserve vision in patients with late-stage, severe age-related macular degeneration.

      Johnson & Johnson is also leveraging its knowledge across all of its sectors to build capabilities in the manufacturing, development and commercialization of a wide range of gene therapies for other parts of the body, Dr. List says: “We’re pioneering potential solutions with gene therapy in eye disease and look forward to extending the technology to someday treat other serious conditions such as heart, liver or kidney disease.”

      More Ways Johnson & Johnson Is Pioneering in Vision Care

      See how the company is committed to helping fight preventable blindness, myopia and more.

      More from Johnson & Johnson

      Innovation
      Two cardiac electrophysiologists performing a cardiac ablation procedure to treat AFib

      What is cardiac ablation?

      For American Heart Month, learn how Johnson & Johnson is innovating to help treat the millions of people who are living with atrial fibrillation and other conditions that cause an irregular heartbeat.
      Latest news
       Biomedical scientist Robert Langer headshot

      Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research

      Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
      Innovation
      Scientist examining a sample in a petri dish

      Could we be on our way to eliminating cancer for good?

      What once seemed like an out-of-reach goal may soon be within our grasp. Take an in-depth look at how Johnson & Johnson is working toward its vision of helping create a world without cancer.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.